↓ Skip to main content

Dove Medical Press

Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer

Overview of attention for article published in OncoTargets and therapy, July 2013
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (71st percentile)
  • Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

twitter
3 X users
patent
1 patent

Citations

dimensions_citation
119 Dimensions

Readers on

mendeley
95 Mendeley
Title
Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer
Published in
OncoTargets and therapy, July 2013
DOI 10.2147/ott.s44906
Pubmed ID
Authors

Gordana Maric, April AN Rose, Matthew G Annis, Peter M Siegel

Abstract

Molecularly targeted therapies are rapidly growing with respect to their clinical development and impact on cancer treatment due to their highly selective anti-tumor action. However, many aggressive cancers such as triple-negative breast cancer (TNBC) currently lack well-defined therapeutic targets against which such agents can be developed. The identification of tumor-associated antigens and the generation of antibody drug-conjugates represent an emerging area of intense interest and growth in the field of cancer therapeutics. Glycoprotein non-metastatic b (GPNMB) has recently been identified as a gene that is over-expressed in numerous cancers, including TNBC, and often correlates with the metastatic phenotype. In breast cancer, GPNMB expression in the tumor epithelium is associated with a reduction in disease-free and overall survival. Based on these findings, glembatumumab vedotin (CDX-011), an antibody-drug conjugate that selectively targets GPNMB, is currently being investigated in clinical trials for patients with metastatic breast cancer and unresectable melanoma. This review discusses the physiological and potential pathological roles of GPNMB in normal and cancer tissues, respectively, and details the clinical advances and challenges in targeting GPNMB-expressing malignancies.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 95 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 95 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 17 18%
Researcher 17 18%
Student > Ph. D. Student 15 16%
Student > Postgraduate 9 9%
Other 7 7%
Other 9 9%
Unknown 21 22%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 23 24%
Agricultural and Biological Sciences 15 16%
Medicine and Dentistry 11 12%
Immunology and Microbiology 7 7%
Neuroscience 5 5%
Other 10 11%
Unknown 24 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 October 2017.
All research outputs
#7,205,554
of 25,374,917 outputs
Outputs from OncoTargets and therapy
#365
of 3,016 outputs
Outputs of similar age
#57,546
of 206,712 outputs
Outputs of similar age from OncoTargets and therapy
#11
of 42 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,712 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.